Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | PRNP | P04156 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 10/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.55 |
| ▸ | GAK | O14976 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349199 | 0.79 | MAPK1 (1.00) | MAPK1KDM4ECYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6186081 | 0.78 | MAPK1 (0.97) | MAPK1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7702775 | 0.78 | EGFR (0.76) | CYP3A4MAPTEGFRERBB2ABCG2 | |
| SCHEMBL30127245 | 0.77 | ALDH1A1 (0.47) | MAPK1KDM4ECYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL7708472 | 0.77 | EGFR (0.77) | CYP3A4MAPTEGFRERBB2ABCG2 | |
| SCHEMBL8225745 | 0.77 | KDM4E (0.73) | MAPK1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4783154 | 0.76 | KDM4E (1.00) | MAPK1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15077994 | 0.76 | RAF1 (0.74) | MAPK1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18292473 | 0.76 | EGFR (0.84) | MAPK1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6796326 | 0.75 | EGFR (0.71) | CYP3A4MAPTEGFRERBB2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11607414-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-03-21 | — | — | US | disclosed |
| EP-3233085-B1 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF EGFR AND PI3K | UNIV MICHIGAN REGENTS (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-30 | — | — | US | disclosed |
| EP-3955923-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | The Regents Of The University Of Michigan (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-113354617-A | Small molecule inhibitors of EGFR and PI3K | 密歇根大学董事会 | 2021-09-07 | — | — | CN | disclosed |
| CN-107531665-B | Small molecule inhibitors of EGFR and PI3K | 密歇根大学董事会 | 2021-03-30 | — | — | CN | disclosed |
| US-20210023085-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-01-28 | — | — | US | disclosed |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-11-24 | — | — | US | disclosed |
| WO-2020215037-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-10-22 | — | — | WO | disclosed |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-06 | — | — | US | disclosed |
| US-10206924-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-12-21 | — | — | US | disclosed |
| EP-3233085-A2 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | The Regents of The University of Michigan (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016100347-A2 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206924-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | MAPK1 138/4885KDM4E 2937/4885CYP1A2 2730/4885 |
| US-20170360788-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | MAPK1 138/4885KDM4E 2937/4885CYP1A2 2730/4885 |
| US-11607414-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | MAPK1 138/4885KDM4E 2937/4885CYP1A2 2730/4885 |
| US-20210023085-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | MAPK1 138/4885KDM4E 2937/4885CYP1A2 2730/4885 |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | MAPK1 138/4885KDM4E 2937/4885CYP1A2 2730/4885 |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | MAPK1 138/4885KDM4E 2937/4885CYP1A2 2730/4885 |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | CD274, PDCD1, PDCD1LG2 | MAPK1 101/4885KDM4E 1364/4885CYP1A2 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.